Hypoxia-induced pulmonary hypertension (PH) is one of the most common and deadliest
forms of PH. Fibroblast growth factor receptors 1 and 2 (FGFR1/2) are elevated in patients …

Pulmonary hypertension (PH) is a progressive, lethal lung disease characterized by
pulmonary artery SMC (PA-SMC) hyperplasia leading to right-sided heart failure. Molecular …

Pulmonary vascular remodeling is key to the pathogenesis of idiopathic pulmonary arterial
hypertension (IPAH). We recently reported that fibroblast growth factor (FGF) 2 is markedly …

Increased glycolysis in the lung vasculature has been connected to the development of
pulmonary hypertension (PH). We therefore investigated whether glycolytic regulator 6 …

Pulmonary hypertension (PH) complicating chronic parenchymal lung disease, such as
idiopathic pulmonary fibrosis, results in significant morbidity and mortality. Since the hypoxia …

Chronic hypoxia frequently complicates the care of patients with interstitial lung disease,
contributing to the development of pulmonary hypertension (PH), and premature death …

Fibroblast growth factor 21 (FGF21), a primarily liver-derived endocrine factor, has the
beneficial effect of protecting blood vessels. Peroxisome proliferator-activated receptor γ …

Idiopathic pulmonary arterial hypertension (IPAH), pulmonary hypertension (PH) due to lung
disease and/or hypoxia and idiopathic pulmonary fibrosis (IPF) are increasingly recognized …

Pulmonary vascular remodeling characterized by concentric wall thickening and intraluminal
obliteration is a major contributor to the elevated pulmonary vascular resistance in patients …

Mutations affecting transforming growth factor-beta (TGF-β) superfamily receptors, activin
receptor-like kinase (ALK)-1, and endoglin (ENG) occur in patients with pulmonary arterial …